Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...

Global demand for Lilly's and Danish rival Novo Nordisk's diabetes and weight-loss drugs has been extraordinary, with the two ...

Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Currently priced at Rs 60 per tablet, Empagliflozin’s generic versions will be available for as low as Rs 9-Rs 14 per tablet, significantly reducing costs for millions of patients, states the report.

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Mounjaro, chemically known as tirzepatide, is currently sold in the ... Ricks told Reuters that it expects to launch Mounjaro, in India as early as next year. Advisory Alert: It has come to ...